The  effect of Tocilizumab on the course and outcome of the disease in patients with COVID-19 pneumonia - experience of a secondary-level hospital

Sladjana M Pavic; Radomir  Slovic; Aleksa Novkovic; Aleksandra Pavic

Sladjana M Pavic Opsta bolnica Uzice, Odeljenje ya infektivne i tropske bolesti
Radomir Slovic Intensive care unit, General Hospital Uzice, Uzice, Republic of Serbia,
Aleksa Novkovic Cener for Neclear Medicine, University Clinical Center of Serbia, Belgrade, Republic of Serbia,
Aleksandra Pavic Center for Radiology, University Clinical Center of Serbia, Belgrade, Republic of Serbia,

Keywords: Tocilizumab, COVID-19 pneumonija, clinical course, predictors of fatal outcome

Abstract

Introduction: The significant role in the progression of COVID-19 pneumonia is played by IL-6. Tocilizumab is a monoclonal antibody that blocks its activity.

The aim was to assess the effect of tocilizumab on the clinical course, laboratory parameters, radiographic changes in COVID-19 pneumonia, and predictors of mortality.

Methods: A retrospective analysis was conducted on data from 340 patients with COVID-19 pneumonia treated with tocilizumab. Data were collected on the day of tocilizumab administration and five days later. Information on sex, age, clinical course, disease outcome, comorbidities, nosocomial infections, oxygenation method, and radiographic changes was gathered. Parameters were compared based on mortality outcomes. Statistical analysis was performed using the SPSS statistical package, v.25.0.

Results: The mean age of patients was 66.22 ± 11.37 years, with 66.4% being male. 65.4% had comorbidities, most commonly arterial hypertension (56.2%). Nosocomial infections were present in 8.5%, bacterial pneumonia being the most frequent (34.5%). Oxygen support was non-invasive in 64.1% of cases, and 24% required mechanical ventilation. 23.8% of patients had an R/F index <200 before tocilizumab, and 15.9% after treatment. The total radiographic score (CXR-SS) before tocilizumab showed severe changes in 71.5%, and very severe in 27.1%. Mortality was 21.8%, with 78.3% of deaths occurring in patients >65 years old. 75.7% of deceased patients had very severe CXR-SS.

Conclusion: Tocilizumab led to improvements in respiratory function and regression of biochemical inflammatory parameters. Age >65, comorbidities, and nosocomial infections were associated with higher mortality, with significant radiographic changes and mechanical ventilation being key predictors of mortality.

Author Biography

Sladjana M Pavic, Opsta bolnica Uzice, Odeljenje ya infektivne i tropske bolesti

Prim. dr sc. med. Sladjana Pavic, specijalista za infektivne i tropske bolesti;

nacelnica odeljenja za infektivne i tropske bolesti OB Uzice;

predsednica Etickog odbora ZC Uzice;

clan Saveta direktora ZC Uzice;

zamenik predsednika Komisije za bolnicke infekcije OB Uzice i clan Komisije za bolnicke infelcije ZC Uzice

References

Raban AA, Al-Ahmed SH, Haque S, et al. SARS-CoV-2, SARS-CoV, and MERS-COV: A comparativeoverview. Infez. Med. 2020; 28 (2): 174-84.
Van den Eynde E, Gasch O, Oliva JC, et al. Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital. Infect Dis. 2021; 53: 291-302. DOI: 10.1080/23744235.2021.1884286.
Bahrini K, Stambouli N, Ben Azaiez M, et al. Immune Cell Response during COVID-19 Infection and following SARS-CoV-2 Vaccination in Patients Admitted to Intensive Care Unit. J Immunol Res. 2023; 2023: 4059484. DOI: 10.1155/2023/4059484.
Shekhawat J, Gauba K, Gupta S, et al. Interleukin-6 Perpetrator of the COVID-19 Cytokine Storm. Indian J Clin Biochem. 2021; 36 (4): 440-50. DOI: 10.1007/s12291-021-00989-8.
Dickov I, Bulatović S, Petrović Đ, et al. Srp Arh Celok Lek. 2024; 152 (7-8): 391-6. DOI: 10.2298/SARH230901048D.
Saha A, Sharma AR, Bhattacharya M, et al. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19. Arch Med Res. 2020; 51 (6): 595-7. DOI: 110.1016/j.arcmed.2020.05.009.
Hansell DM, Bankier AA, MacMahon H, et al. Fleischner Society: Glossary of Terms for Thoracic Imaging. Radiology 2008; 246 (3): 697-722. DOI: 10.1148/radiol.2462070712.
Warren MA, Zhao Z, Koyama T, et al. Severity scoring of lung oedema on the chest radiograph is associated with clinical outcomes in ARDS. Thorax 2018; 73 (9): 840-6. DOI: 10.1136/thoraxjnl-2017-211280.
Li X, Mi Z, Liu Z, et al. SARS-CoV-2: pathogenesis, therapeutics, variants, and vaccines. Front Microbiol. 2024; 15: 1334152. DOI: 10.3389/fmicb.2024.133415.
Schmidt W, Pawlak-Buś K, Jóźwiak B, et al. Identification of Clinical Response Predictors of Tocilizumab Treatment in Patients with Severe COVID-19 Based on Single-Center Experience. J Clin Med. 2023; 12 (6): 2429. DOI: 10.3390/jcm12062429.
Kaya H, Öksüzler Kızılbay G, Ilgazlı AH, et al. Tocilizumab in hospitalized patients with severe COVID-19 pneumonia: A single-center observational study. Eurasian J Pulmonol 2024; 26 (2): 41-50. DOI: 10.14744/ejp.2023.4009.
Georgakopoulou VE, Basoulis D, Voutsinas PM, et al. Factors predicting poor outcomes of patients treated with tocilizumab for COVID 19 associated pneumonia: A retrospective study. Exp Ther Med. 2022; 24 (6): 724. DOI: 10.3892/etm.2022.11660.
Milošević I, Barać A, Jovanović J, et al. A single-center experience of early administration of tocilizumab and corticosteroids in patients with COVID-19 pneumonia. Trans R Soc Trop Med Hyg. 2023; 117 (9): 668-72. DOI: 10.1093/trstmh/trad026.
Taslem MJ, Anwar S, Hosen MJ. The sex and gender dimensions of COVID-19: A narrative review of the potential underlying factors. Infect Genet Evol. 2022; 103: 105338. DOI: 10.1016/j.meegid.2022.105338.
Bahrini K, Larbi HBC, Azaiez MB, et al. Efficacy and Safety of Tocilizumab Treatment in Tunisian Critically Ill COVID-19 Patients. Journal of Immunology Research. 2024; Article ID 2585821. DOI: 10.1155/2024/2585821
Pavić A, Janković I, Novković A. Severity of radiographic changes in patients with COVID-19 pneumonia - experience from secondary-level hospital.Srp Arh Celok Lek. 2024; 152 (9-10): 450-5. DOI: 10.2298/SARH240318067P.
Masotti L, Landini G, Panigada G, et al. Department of Medical Specialties of Azienda USL Toscana Centro Covid-19 Group. Predictors of poor outcome in tocilizumab treated patients with Sars-CoV-2 related severe respiratory failure: A multicentre real world study. Int Immunopharmacol. 2022; 107: 108709. DOI: 10.1016/j.intimp.2022.108709.
Gazibara T, Beronja B, Karan A, et al. Acinetobacter baumannii pneumonia associated with mechanical ventilation due to COVID-19: epidemiology, clinical characteristics and therapy. Medical Research. 2024; 57 (3): 129-36. DOI: 10.5937/medi57-49490.
Ronit A, Berg RMG, Bay JT, et al. Compartmental immunophenotyping in COVID-19 ARDS: a case series. J. Allergy Clin. Immunol. 2021; 147 (1): 81–91. DOI: 10.1016/j.jaci.2020.09.009.
Elsharnouby NM, Elgendy MA, Elrahman HMA , et al. Efficacy and Safety of Tocilizumab with Methylprednisolone versus Methylprednisolone Only as a Treatment for Severe Covid-19 Patients, QJM: An International Journal of Medicine. 2024; 117 (1): hcae070.065. DOI: 10.1093/qjmed/hcae070.065.
Adzic-Vukicevic T, Markovic D, Reljic A, et al. What did we learn about tocilizumab use against COVID-19? A single-center observational study from an intensive care unit in Serbia. Front Med (Lausanne). 2023; 10: 1253135. DOI: 10.3389/fmed.2023.1253135.
Anci C, Solavallone V, Cardone R, et al. Use of tocilizumab in COVID-19 pneumonia hospitalized patients. Cohort study. Acta Colombiana de Cuidado Intensivo. 2023; 23 (2): 105–12. DOI: 10.1016/j.acci.2022.10.004.
Lacedonia D, Tondo P, Scioscia G, et al. Imaging Profile After Treatment with Tocilizumab in COVID-19: A Case Series. Curr Med Imaging. 2023; 19 (8): 939-44. DOI: 10.2174/1573405618666220819121114.
Schmidt W, Pawlak-Buś K, Jóźwiak B, et al. Development and validation of COVID-19 Radiological Risk Score (COVID-RRS): a multivariable radiological score to estimate the in-hospital mortality risk in COVID-19 patients. Eur Rev Med Pharmacol Sci. 2023; 27 (1): 384-94. DOI: 10.26355/eurrev_202301_30892.
Cvetanovic V, Cvetanovic M, Milenkovic N, et al. Influence of Tocilizumab on Respiratory Support Requirements in non ICU COVID-19 Patients. Int. J. Collab. Res. Intern. Med. Public Health. 2023; 15 (1): 1-5. DOI:10.35248/1840-4529.23.
Moosazadeh M, Mousavi T. Combination therapy of tocilizumab and steroid for COVID-19 patients: A meta-analysis. J Med Virol. 2022; 94 (4): 1350-6. DOI: 10.1002/jmv.27489.
Moreno Diaz R, Amor Garcia MA, Teigell Munoz FJ, et al. Does timing matter on tocilizumab administration? Clinical, analytical and radiological outcomes in COVID-19. Eur J Hosp Pharm. 2022; 29 (6):340-5. DOI: 10.1136/ejhpharm-2020-002669.
Tsai A, Diawara O, Nahass RG, et al. Impact of tocilizumab administration on mortality in severe COVID-19. Sci Rep. 2020; 10: 19131. DOI: 10.1038/s41598-020-76187-y.
RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021; 397 (10285): 1637-45. DOI: 10.1016/S0140-6736(21)00676-0.
Milošević I, Beronja B. The use of tocilizumab in severe covid-19: a comprehensive review Medical Research. 2024; 57 (2): 173-82 DOI: 10.5937/medi57-48405.